| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2002;106:653.)
© 2002 American Heart Association, Inc.
Clinical Investigation and Reports |
From the Cardiology Branch (J.P.J.H., W.H.S., G.Z., R.M., A.P., K.R.A.N., A.A.Q.), Office of Biostatistics Research (M.A.W.), National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Md.
Correspondence to Arshed A. Quyyumi, MD, Professor of Medicine (Cardiology), Emory University Hospital, Suite F606, 1364 Clifton Rd NE, Atlanta, GA 30322. E-mail aquyyum{at}emory.edu
| Abstract |
|---|
|
|
|---|
Methods and Results We measured the change in coronary vascular resistance (
CVR) and epicardial diameter with intracoronary acetylcholine (ACh, 15 µg/min) to test endothelium-dependent function and sodium nitroprusside (20 µg/min) and adenosine (2.2 mg/min) to test endothelium-independent vascular function in 308 patients undergoing cardiac catheterization (132 with and 176 without CAD). Patients underwent clinical follow-up for a mean of 46±3 months. Acute vascular events occurred in 35 patients. After multivariate analysis that included CAD and conventional risk factors for atherosclerosis,
CVR with ACh (P=0.02) and epicardial constriction with ACh (P=0.003), together with increasing age, CAD, and body mass index, were independent predictors of adverse events. Thus, patients in the tertile with the best microvascular responses with ACh and those with epicardial dilation with ACh had improved survival by Kaplan-Meier analyses in the total population, as did those in the subset without CAD. Similar improvement in survival was also observed when all adverse events, including revascularization, were considered. Endothelium-independent responses were not predictive of outcome.
Conclusions Epicardial and microvascular coronary endothelial dysfunction independently predict acute cardiovascular events in patients with and without CAD, providing both functional and prognostic information that complements angiographic and risk factor assessment.
Key Words: atherosclerosis coronary disease endothelium prognosis infarction
| Introduction |
|---|
|
|
|---|
See p 640
In agreement with this expectation, recent studies have demonstrated that coronary vascular dysfunction independently predicts adverse long-term cardiovascular prognosis where the majority of "adverse events" were revascularization procedures.5,6 We therefore undertook the present study to investigate whether the presence of coronary vascular endothelial dysfunction in patients with angiographically normal coronary arteries (NCAs) or those with CAD predicted a worse long-term outcome from unpredictable acute cardiovascular events, including death, myocardial infarction, stroke, and unstable angina.
| Methods |
|---|
|
|
|---|
3 months), severe valvular disease, New York Heart Association class III to IV heart failure, or unrevascularized 3-vessel or left main disease were excluded. Subjects who were referred for revascularization after cardiac catheterization were also excluded.
CAD was defined as angiographic evidence of irregularity, plaque formation, or stenosis in any epicardial coronary artery. Patients with angiographically smooth coronary arteries represented a group with NCAs. Cardiac risk factors assessed included age, sex, presence of left ventricular dysfunction, tobacco smoking, diabetes, hypercholesterolemia, hypertension, and body mass index. Smokers included subjects with a current or prior history of tobacco use. Diabetes was defined as a fasting blood glucose level >140 mg/dL or treatment with dietary modification, insulin, or oral hypoglycemic agents at the time of the study. Hypercholesterolemia was defined as a fasting serum total cholesterol >240 mg/dL or if the subject was being treated with lipid-lowering medication or dietary modification. Hypertension was defined as a seated systolic blood pressure
140 mm Hg or diastolic pressure
90 mm Hg on at least 3 occasions, or if such a diagnosis had been made in the past and the patient was being treated with medications or lifestyle modification. Left ventricular dysfunction was defined as resting left ventricular ejection fraction <40% by radionuclide angiography or echocardiography. Body mass index was calculated as weight (kg) divided by height (m)2.
Coronary Vascular Function
All cardiac medications were withdrawn
48 hours and at least 5 half lives before the study. ACE inhibitors and aspirin or other cyclooxygenase inhibitors were discontinued
7 days before the study. After diagnostic coronary angiography, a 3F infusion catheter was introduced via a 7F guide catheter into a nonobstructed coronary artery (stenosis severity
30%). Blood flow velocity was measured, as previously described, with a 0.014- or 0.018-in Doppler wire (FloWire, EndoSonics).7 To calculate coronary blood flow (CBF), epicardial diameter was measured in a 0.25- to 0.5-cm segment of vessel beginning 0.25 cm beyond the tip of the flow wire. Coronary vascular resistance (CVR) was calculated as mean arterial pressure divided by CBF. Quantitative angiography was performed by an observer blinded to the identity of the study infusion with ARTREK software (Quantim 2001, StatView, ImageComm Systems, Inc) or the PIE medical CAAS system.3 Additionally, mid and distal segments of epicardial coronary arteries were also measured after each intervention, and epicardial coronary responses were determined by assessment of the percent change in diameter (
Diam), with each drug compared with baseline, in a segment of the mid or distal portion of the study vessel that was straight and free of overlap or major branch points.
Endothelium-dependent vasodilation was determined during a 2-minute intracoronary infusion of acetylcholine (ACh) at 15 µg/min (estimated concentration 10-6 mol/L). Ten minutes after the ACh infusion, endothelium-independent function was estimated during a 3-minute intracoronary infusion of 20 µg/min sodium nitroprusside (SNP, n=241), followed by measurement of vasodilator reserve with a 2-minute infusion of 2.2 mg/min of adenosine (n=270). Study drug doses were doubled when infused directly into the left main-stem coronary artery.
Long-Term Follow-Up
Long-term follow up was performed either by a questionnaire or by telephone contact. All cardiovascular events were validated by review of medical records, ECG, and cardiac enzyme data. The minimum follow-up period was 6 months. For subjects experiencing more than 1 acute event, only the first event was considered in the analysis.
The combined acute cardiovascular event end points assessed during follow-up included cardiovascular death, acute myocardial infarction, unstable angina pectoris, and acute ischemic stroke. Cardiovascular death was defined as death due to a myocardial or cerebral infarction or documented sudden cardiac death. Myocardial infarction was defined as an elevation of creatine kinase levels >2 times the upper limit with or without new ST-segment elevation (>0.1 mV) in at least 2 contiguous leads. Unstable angina pectoris was defined as hospitalization because of angina pectoris that occurred at rest and that was associated with ECG changes (Braunwald classification IIB or IIIB). Ischemic stroke was defined as clinical and radiological evidence of stroke without intracranial hemorrhage.
Statistical Analysis
Data are expressed as mean±SEM. Differences between means were compared by unpaired Students t test. Cumulative acute cardiovascular event rates were estimated by Kaplan-Meier survival curves (Lifetest procedure of SAS8). Probability values for survival curve comparisons were calculated with the log-rank statistic. Cox proportional hazards multivariate stepwise regression analysis (SAS) was used to determine the univariate and multivariate relationships between clinical variables and acute cardiovascular events during the follow-up period. Covariates entered in this regression model were
CVR with ACh, SNP, or adenosine;
Diam with SNP or epicardial dilation/constriction with ACh; and presence of coronary atherosclerosis, age, sex, presence of left ventricular dysfunction, diabetes, smoking, hypertension, hypercholesterolemia, and family history of CAD. All probability values were 2-tailed, and a value <0.05 was considered statistically significant.
| Results |
|---|
|
|
|---|
|
|
Clinical Determinants of Acute Cardiovascular Events
Increasing age, male sex, CAD, increased body mass index, hypercholesterolemia, diabetes, left ventricular dysfunction, and smoking were univariate predictors of acute cardiovascular events by Cox proportional hazards analysis (Table 3). CAD, increasing age, and increased body mass index remained significant independent predictors of acute events after multivariate analysis adjusted for other covariates in the full model, with a nonsignificant trend observed for smokers (P=0.07; Table 3).
|
Coronary Vascular Function and Acute Cardiovascular Events
Microcirculation
Microvascular dilation with ACh was attenuated in subjects with acute events during follow-up compared with those without events (CBF increase 67±12% and CVR fall of 28±6% compared with 114±6% increase in CBF [P=0.007] and 46±2% fall in CVR [P=0.007] in subjects with and without events, respectively). To study the relationship between coronary microvascular endothelial function and acute cardiovascular events, the study population was divided into tertiles according to the
CVR with ACh. By Kaplan-Meier analysis, event-free survival from acute cardiovascular events was significantly associated with the vasodilator response to ACh (P=0.047), with outcome being worse in those with a more depressed vasodilator response (Figure 1). When the 2 tertiles with impaired responses to ACh were compared with the best-responding tertile, the difference in outcome was more significant (P=0.017). In contrast, when the population was similarly divided into tertiles according to response to the endothelium-independent vasodilators, no significant association was observed between event-free survival from acute cardiovascular events and
CVR with either SNP or adenosine (P=0.11; Figure 1).
|
After multivariate adjustment for all noted cardiac risk factors,
CVR with ACh remained an independent predictor of event-free survival (P=0.019), whereas responses to SNP and adenosine were not (P=0.24 and P=0.08, respectively). To determine the value of coronary microvascular endothelial function in predicting acute cardiovascular events, we compared event rates in subjects in the top versus the lower 2 tertiles of the ACh response (increase in CBF was <130% and fall in CVR was <56% in response to ACh in patients in the lower 2 tertiles). The event rate of patients in the lower 2 tertiles was 14.1% compared with 5.8% for those in the upper tertile.
The frequency of all cardiovascular events that included both elective revascularization procedures and acute events was also investigated in the 3 tertiles according to
CVR with ACh. Event-free survival from all cardiovascular events was also significantly worse in the 2 tertiles with relatively impaired coronary microvascular endothelial function than in those in the tertile with preserved function (P=0.035; Figure 2). Finally, when only death, myocardial infarction, or stroke were considered as events, event-free survival was also significantly related to endothelial function (P=0.037 by Kaplan-Meier analysis; Figure 2).
|
Epicardial Circulation
To study the relationship between acute events and epicardial endothelial function, the study population was divided into 2 groups: those who constricted with ACh (
Diam <0%, n=153), which denoted endothelial dysfunction, and those who dilated (
Diam
0%; n=138), which denoted preserved endothelial function.1,35 The incidence of acute events was significantly greater in subjects with epicardial constriction than in those who dilated with ACh (P=0.003 by Kaplan-Meier analysis; Figure 3). The event rate in those with a constrictor response was 13% compared with 9.4% in those with dilation in response to ACh. However, when the population was divided into tertiles according to
Diam with the endothelium-independent vasodilator SNP, there was no difference in event-free survival from acute coronary vascular events during follow-up (P=0.33; Figure 3). After multivariate adjustment for risk factors, epicardial vasodilation with ACh remained an independent predictor of event-free survival (P=0.019), whereas
Diam with SNP was not (P=0.71).
|
The frequency of all cardiovascular events including revascularization procedures was also investigated according to the epicardial response with ACh. Event-free survival from all events was significantly worse in those exhibiting epicardial vasoconstriction with ACh than in those who had vasodilation in response to ACh (P<0.0001; Figure 2). Additionally, when only death, myocardial infarction, or stroke were considered as events, event-free survival was also significantly worse in those who had vasoconstriction with ACh (P=0.038; Figure 2).
Outcome in CAD and NCA Patients
Because of the observed independent relationship between the presence of CAD and worse prognosis, we investigated whether the relationship between endothelium-dependent vasomotion and prognosis was independent of the presence or absence of CAD by introducing interaction terms (CAD x
CVR or CAD x epicardial constriction/dilation with ACh) in the regression analysis. No significant interaction was observed (P=0.87 and P=0.77, respectively), which indicated that endothelial dysfunction predicted outcome independent of the presence of CAD.
To further determine the relationship between coronary vascular endothelial function and prognosis, we investigated whether
CVR with ACh also predicted outcome in the subset of 171 subjects with NCAs. When this subgroup was divided into tertiles according to
CVR with ACh, the tertile with the best response had a better event-free survival than those in the 2 lower tertiles (Figure 4). When patients with NCAs were divided into 2 groups according to whether they exhibited a dilator or constrictor epicardial response to ACh, a nonsignificant trend toward a better event-free survival from acute coronary events was observed in those who had dilation with ACh (Figure 4).
|
Because aspirin, ACE inhibitors, and HMG-CoA reductase inhibitors may alter endothelial function and are commonly used to treat subjects with CAD, Kaplan-Meier analyses were performed to assess the influence of these therapies. No differences in the incidence of acute events were observed in patients with CAD who were taking ACE inhibitors (P=0.372), HMG-CoA reductase inhibitors (P=0.275), or aspirin (P=0.296) compared with those not taking these medications. There were no differences in the use of these agents in patients divided into tertiles based on their ACh response or in those with epicardial constriction or dilation in response to ACh.
| Discussion |
|---|
|
|
|---|
Based on our findings, within our follow-up period, 14% of patients in the lower 2 tertiles of the microvascular ACh response (CBF increase <130%) had acute events, and 21% had events including revascularization (positive predictive value). Thus, 83% of all acute events and 77% of events including revascularization occurred in patients within these lower 2 tertiles. Moreover, 94% of patients in the top tertile remained free of acute events, and 87% were free of all events, including revascularization. Similar findings were observed when epicardial responses to ACh were considered.
The acute event rate observed in the cohort in the present study was 3% per year, similar to the event rate observed in the HOPE (Heart Outcomes Prevention Evaluation) trial, which recruited a study population with similar clinical characteristics to ours.9 Although an adverse cardiovascular prognosis has been described in subjects with coronary vascular dysfunction in 2 previous studies, both study populations were approximately half the size of the present cohort, subjects with NCAs were underrepresented, a relatively small number of events occurred, and a substantial proportion of the reported events were revascularization procedures.5,6 Suwaidi et al6 presented the prognostic value of coronary microvascular responses to ACh without independently determining the value of endothelium-independent or diameter responses. Furthermore, Schachinger et al5 limited their observations to the epicardial coronary circulation, where the endothelium-independent response to SNP appeared to be a better predictor of prognosis than the ACh response. In contrast, the present study population was considerably larger; we separately analyzed acute unpredictable cardiovascular events; the population with NCAs could be studied independently; and we clearly demonstrated differences in the association between endothelium-dependent and -independent function and long-term cardiovascular prognosis.
The vascular endothelium secretes multiple factors that not only regulate vascular tone but also modulate platelet activity, the endogenous thrombolytic system, vascular inflammation, and cell migration and proliferation.1 Because the coronary vasodilator response to ACh is predominantly caused by release of NO from endothelial cells, and the impaired response to ACh is primarily caused by reduced bioactivity of NO, we used this measure as an index of endothelial health.3,4 We now show that an increased risk of acute lesion progression leading to cardiovascular events may be predicted by the health of the endothelial lining in both the conductance and resistance vessels. This scenario offers new hope for identifying a subgroup of patients at increased risk from within a cohort of low-risk subjects with and without CAD.
Endothelial cells appear to integrate the injury imposed by exposure to the commonly known risk factors of CAD, the more novel factors such as infections, and other as yet undiscovered genetic and environmental risk factors.10,11 Endothelial dysfunction is associated with increased inflammation,12 thrombogenicity,1316 and enhanced local expression of matrix metalloproteinases,1719 which together increase the vulnerability of atherosclerotic plaques to rupture and thrombus formation, thus providing a mechanistic link between endothelial dysfunction and adverse cardiovascular outcome. Whether patients with endothelial dysfunction have more rapidly progressive atherosclerosis, as suggested by our data, will require confirmation in a prospective angiographic study. Likewise, these data raise another intriguing question: will interventions such as exercise, diet, and pharmacological therapy that are designed to enhance endothelial function also improve prognosis, as is suggested by outcome trials with aspirin, ACE antagonists, and statin therapy?9,2022
Study Limitations
This study was conducted retrospectively and will therefore require confirmation in a prospective investigation. Our results cannot be extended to all subjects with CAD, because we included only medically managed patients with asymptomatic or mildly symptomatic CAD of mild to moderate severity. Unlike previous studies, patients who were referred for revascularization after angiography were not included, to avoid bias introduced by the revascularization strategy.5 Although we excluded subjects with more severe CAD, the independent association between significant multivessel CAD and an adverse cardiovascular prognosis has been well established in such patients.
We are unable to rule out intimal thickening or eccentric plaque formation in the present NCA cohort. It is likely that a number of these patients who also had exposure to conventional risk factors indeed had early atherosclerosis. However, intimal thickening demonstrated by ultrasound has not been helpful in predicting cardiovascular events in subjects with nonobstructed coronary arteries.6 Nevertheless, the present data provide an important clinical lesson: the presence of angiographically smooth epicardial coronary arteries can be associated with endothelial dysfunction, and the degree of dysfunction is an important predictor of outcome in these patients.
Conclusions and Clinical Implications
We have demonstrated a strong association between coronary vascular endothelial dysfunction and an adverse long-term cardiovascular prognosis. Both conduit arterial and microcirculatory endothelial function are predictive of outcome independent of the presence of CAD and its risk factors. Thus, assessment of endothelial function or its markers may help identify a subgroup of patients at high risk. Whether strategies that improve endothelial dysfunction will uniformly improve prognosis needs to be studied prospectively.
Received April 15, 2002; revision received May 21, 2002; accepted May 24, 2002.
| References |
|---|
|
|
|---|
2. Prasad A, Husain S, Schenke W, et al. Contribution of bradykinin receptor dysfunction to abnormal coronary vasomotion in humans. J Am Coll Cardiol. 2000; 36: 14671473.
3. Quyyumi AA, Dakak N, Andrews NP, et al. Nitric oxide activity in the human coronary circulation: impact of risk factors for coronary atherosclerosis. J Clin Invest. 1995; 95: 17471755.[Medline] [Order article via Infotrieve]
4. Quyyumi AA, Dakak N, Mulcahy D, et al. Nitric oxide activity in the atherosclerotic human coronary circulation. J Am Coll Cardiol. 1997; 29: 308317.[Abstract]
5. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000; 101: 18991906.
6. Suwaidi JA, Hamasaki S, Higano ST, et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000; 101: 948954.
7. Doucette JW, Corl PD, Payne HM, et al. Validation of a Doppler guide wire for intravascular measurement of coronary artery flow velocity. Circulation. 1992; 85: 18991911.
8. SAS Institute Inc. SAS Users Guide: Statistics, Version 6.12. Cary, NC: SAS Institute Inc; 1996.
9. Yusuf S, Sleight P, Pogue J, et al, for the Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000; 342: 145153.
10. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000; 87: 840844.
11. Mugge A, Elwell JH, Peterson TE, et al. Release of intact endothelium-derived relaxing factor depends on endothelial superoxide dismutase activity. Am J Physiol. 1991; 260: C219C225.[Medline] [Order article via Infotrieve]
12. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997; 336: 10661071.
13. Newby DE, Wright RA, Dawson P, et al. The L-arginine/nitric oxide pathway contributes to the acute release of tissue plasminogen activator in vivo in man. Cardiovasc Res. 1998; 38: 485492.
14. Newby DE, McLeod AL, Uren NG, et al. Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: direct link between endothelial dysfunction and atherothrombosis. Circulation. 2001; 103: 19361941.
15. Jern S, Wall U, Bergbrant A, et al. Endothelium-dependent vasodilation and tissue-type plasminogen activator release in borderline hypertension. Arterioscler Thromb Vasc Biol. 1997; 17: 33763383.
16. Diodati JG, Dakak N, Gilligan DM, et al. Effect of atherosclerosis on endothelium-dependent inhibition of platelet activation in humans. Circulation. 1998; 98: 1724.
17. Rajavashisth TB, Liao JK, Galis ZS, et al. Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1-matrix metalloproteinase. J Biol Chem. 1999; 274: 1192411929.
18. Rajagopalan S, Meng XP, Ramasamy S, et al. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro: implications for atherosclerotic plaque stability. J Clin Invest. 1996; 98: 25722579.[Medline] [Order article via Infotrieve]
19. Galis ZS, Sukhova GK, Lark MW, et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994; 94: 24932503.[Medline] [Order article via Infotrieve]
20. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344: 13831389.[CrossRef][Medline] [Order article via Infotrieve]
21. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998; 339: 13491357.
22. Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994; 308: 81106.
This article has been cited by other articles:
![]() |
M. Klosinska, T. Rudzinski, P. Grzelak, L. Stefanczyk, J. Drozdz, and M. Krzeminska-Pakula Endothelium-dependent and -independent vasodilation is more attenuated in ischaemic than in non-ischaemic heart failure Eur J Heart Fail, July 3, 2009; (2009) hfp091v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P. Schneider, M. Ritt, U. Raff, C. Ott, and R. E. Schmieder Gender is related to alterations of renal endothelial function in type 2 diabetes Nephrol. Dial. Transplant., June 30, 2009; (2009) gfp318v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Lavi, A. Karasik, N. Koren-Morag, H. Kanety, M. S. Feinberg, and M. Shechter The acute effect of various glycemic index dietary carbohydrates on endothelial function in nondiabetic overweight and obese subjects. J. Am. Coll. Cardiol., June 16, 2009; 53(24): 2283 - 2287. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Seddon, N. Melikian, R. Dworakowski, H. Shabeeh, B. Jiang, J. Byrne, B. Casadei, P. Chowienczyk, and A. M. Shah Effects of Neuronal Nitric Oxide Synthase on Human Coronary Artery Diameter and Blood Flow In Vivo Circulation, May 26, 2009; 119(20): 2656 - 2662. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Gulati, R. M. Cooper-DeHoff, C. McClure, B. D. Johnson, L. J. Shaw, E. M. Handberg, I. Zineh, S. F. Kelsey, M. F. Arnsdorf, H. R. Black, et al. Adverse Cardiovascular Outcomes in Women With Nonobstructive Coronary Artery Disease: A Report From the Women's Ischemia Syndrome Evaluation Study and the St James Women Take Heart Project Arch Intern Med, May 11, 2009; 169(9): 843 - 850. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Zhang, D. A. Ingram, M. P. Murphy, M. R. Saadatzadeh, L. E. Mead, D. N. Prater, and J. Rehman Release of proinflammatory mediators and expression of proinflammatory adhesion molecules by endothelial progenitor cells Am J Physiol Heart Circ Physiol, May 1, 2009; 296(5): H1675 - H1682. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Y. Stokes, T. R. Dugas, Y. Tang, H. Garg, E. Guidry, and N. S. Bryan Dietary nitrite prevents hypercholesterolemic microvascular inflammation and reverses endothelial dysfunction Am J Physiol Heart Circ Physiol, May 1, 2009; 296(5): H1281 - H1288. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Phan, C. Shufelt, and C. N. B. Merz Persistent Chest Pain and No Obstructive Coronary Artery Disease JAMA, April 8, 2009; 301(14): 1468 - 1474. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. E. Gates, W. D. Strain, and A. C. Shore Human endothelial function and microvascular ageing Exp Physiol, March 1, 2009; 94(3): 311 - 316. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. M. Haram, O. J. Kemi, S. J. Lee, M. O. Bendheim, Q. Y. Al-Share, H. L. Waldum, L. J. Gilligan, L. G. Koch, S. L. Britton, S. M. Najjar, et al. Aerobic interval training vs. continuous moderate exercise in the metabolic syndrome of rats artificially selected for low aerobic capacity Cardiovasc Res, March 1, 2009; 81(4): 723 - 732. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Steffel and T. F. Luscher Predicting the Development of Atherosclerosis Circulation, February 24, 2009; 119(7): 919 - 921. [Full Text] [PDF] |
||||
![]() |
J. P.J. Halcox, A. E. Donald, E. Ellins, D. R. Witte, M. J. Shipley, E. J. Brunner, M. G. Marmot, and J. E. Deanfield Endothelial Function Predicts Progression of Carotid Intima-Media Thickness Circulation, February 24, 2009; 119(7): 1005 - 1012. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. G. Schwartz and O. Wexler Early identification and monitoring progression of Chagas' cardiomyopathy with SPECT myocardial perfusion imaging. J. Am. Coll. Cardiol. Img., February 1, 2009; 2(2): 173 - 175. [Full Text] [PDF] |
||||
![]() |
P. Ochodnicky, R. H. Henning, H. Buikema, A. C. A. Kluppel, M. van Wattum, D. de Zeeuw, and R. P. E. van Dokkum Renal endothelial function and blood flow predict the individual susceptibility to adriamycin-induced renal damage Nephrol. Dial. Transplant., February 1, 2009; 24(2): 413 - 420. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Billecke, L. G. D'Alecy, R. Platel, S. E. Whitesall, K. A. Jamerson, R. L. Perlman, and C. A. Gadegbeku Blood content of asymmetric dimethylarginine: new insights into its dysregulation in renal disease Nephrol. Dial. Transplant., February 1, 2009; 24(2): 489 - 496. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. A. Tyldum, I. E. Schjerve, A. E. Tjonna, I. Kirkeby-Garstad, T. O. Stolen, R. S. Richardson, and U. Wisloff Endothelial dysfunction induced by post-prandial lipemia: complete protection afforded by high-intensity aerobic interval exercise. J. Am. Coll. Cardiol., January 13, 2009; 53(2): 200 - 206. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Volzke, D. M. Robinson, T. Spielhagen, M. Nauck, A. Obst, R. Ewert, B. Wolff, H. Wallaschofski, S. B. Felix, and M. Dorr Are serum thyrotropin levels within the reference range associated with endothelial function? Eur. Heart J., January 2, 2009; 30(2): 217 - 224. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. E. Tjonna, S. J. Lee, O. Rognmo, T. O. Stolen, A. Bye, P. M. Haram, J. P. Loennechen, Q. Y. Al-Share, E. Skogvoll, S. A. Slordahl, et al. Aerobic Interval Training Versus Continuous Moderate Exercise as a Treatment for the Metabolic Syndrome: A Pilot Study Circulation, July 22, 2008; 118(4): 346 - 354. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ashfaq, J. L. Abramson, D. P. Jones, S. D. Rhodes, W. S. Weintraub, W. C. Hooper, V. Vaccarino, R. W. Alexander, D. G. Harrison, and A. A. Quyyumi Endothelial Function and Aminothiol Biomarkers of Oxidative Stress in Healthy Adults Hypertension, July 1, 2008; 52(1): 80 - 85. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. R. Pries, H. Habazettl, G. Ambrosio, P. R. Hansen, J. C. Kaski, V. Schachinger, H. Tillmanns, G. Vassalli, I. Tritto, M. Weis, et al. A review of methods for assessment of coronary microvascular disease in both clinical and experimental settings Cardiovasc Res, June 25, 2008; (2008) cvn136v2. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. Seddon, P. J. Chowienczyk, S. E. Brett, B. Casadei, and A. M. Shah Neuronal Nitric Oxide Synthase Regulates Basal Microvascular Tone in Humans In Vivo Circulation, April 15, 2008; 117(15): 1991 - 1996. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Stangl, V. Witzel, G. Baumann, and K. Stangl Current diagnostic concepts to detect coronary artery disease in women Eur. Heart J., March 2, 2008; 29(6): 707 - 717. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Terashima, P. K. Nguyen, G. D. Rubin, C. Iribarren, B. K. Courtney, A. S. Go, S. P. Fortmann, and M. V. McConnell Impaired coronary vasodilation by magnetic resonance angiography is associated with advanced coronary artery calcification. J. Am. Coll. Cardiol. Img., March 1, 2008; 1(2): 167 - 173. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. V. Brauner, L. Forchhammer, P. Moller, L. Barregard, L. Gunnarsen, A. Afshari, P. Wahlin, M. Glasius, L. O. Dragsted, S. Basu, et al. Indoor Particles Affect Vascular Function in the Aged: An Air Filtration-based Intervention Study Am. J. Respir. Crit. Care Med., February 15, 2008; 177(4): 419 - 425. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. I. Worthley, R. S. Kanani, Y.-H. Sun, Y. Sun, D. M. Goodhart, M. J. Curtis, and T. J. Anderson Effects of tetrahydrobiopterin on coronary vascular reactivity in atherosclerotic human coronary arteries Cardiovasc Res, December 1, 2007; 76(3): 539 - 546. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Briet, C. Collin, S. Laurent, A. Tan, M. Azizi, M. Agharazii, X. Jeunemaitre, F. Alhenc-Gelas, and P. Boutouyrie Endothelial Function and Chronic Exposure to Air Pollution in Normal Male Subjects Hypertension, November 1, 2007; 50(5): 970 - 976. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Naya, T. Tsukamoto, K. Morita, C. Katoh, T. Furumoto, S. Fujii, N. Tamaki, and H. Tsutsui Olmesartan, But Not Amlodipine, Improves Endothelium-Dependent Coronary Dilation in Hypertensive Patients J. Am. Coll. Cardiol., September 18, 2007; 50(12): 1144 - 1149. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. de Bree, L. A van Mierlo, and R. Draijer Folic acid improves vascular reactivity in humans: a meta-analysis of randomized controlled trials Am. J. Clinical Nutrition, September 1, 2007; 86(3): 610 - 617. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Tornqvist, N. L. Mills, M. Gonzalez, M. R. Miller, S. D. Robinson, I. L. Megson, W. MacNee, K. Donaldson, S. Soderberg, D. E. Newby, et al. Persistent Endothelial Dysfunction in Humans after Diesel Exhaust Inhalation Am. J. Respir. Crit. Care Med., August 15, 2007; 176(4): 395 - 400. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Shenouda and J. A. Vita Effects of Flavonoid-Containing Beverages and EGCG on Endothelial Function J. Am. Coll. Nutr., August 1, 2007; 26(4): 366S - 372S. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. V. Joffe, R. Y. Kwong, M. D. Gerhard-Herman, C. Rice, K. Feldman, and G. K. Adler Beneficial Effects of Eplerenone Versus Hydrochlorothiazide on Coronary Circulatory Function in Patients with Diabetes Mellitus J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2552 - 2558. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Saam, T. S. Hatsukami, N. Takaya, B. Chu, H. Underhill, W. S. Kerwin, J. Cai, M. S. Ferguson, and C. Yuan The Vulnerable, or High-Risk, Atherosclerotic Plaque: Noninvasive MR Imaging for Characterization and Assessment Radiology, July 1, 2007; 244(1): 64 - 77. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. D. Robinson, C. A. Ludlam, N. A. Boon, and D. E. Newby Endothelial Fibrinolytic Capacity Predicts Future Adverse Cardiovascular Events in Patients With Coronary Heart Disease Arterioscler. Thromb. Vasc. Biol., July 1, 2007; 27(7): 1651 - 1656. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Wisloff, A. Stoylen, J. P. Loennechen, M. Bruvold, O. Rognmo, P. M. Haram, A. E. Tjonna, J. Helgerud, S. A. Slordahl, S. J. Lee, et al. Superior Cardiovascular Effect of Aerobic Interval Training Versus Moderate Continuous Training in Heart Failure Patients: A Randomized Study Circulation, June 19, 2007; 115(24): 3086 - 3094. [Abstract] [Full Text] [PDF] |
||||
![]() |
Authors/Task Force Members:, G. Mancia, G. De Backer, A. Dominiczak, R. Cifkova, R. Fagard, G. Germano, G. Grassi, A. M. Heagerty, S. E. Kjeldsen, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur. Heart J., June 11, 2007; (2007) ehm236v1. [Full Text] [PDF] |
||||
![]() |
S. J Hamilton, G. T Chew, and G. F Watts Therapeutic regulation of endothelial dysfunction in type 2 diabetes mellitus Diabetes and Vascular Disease Research, June 1, 2007; 4(2): 89 - 102. [Abstract] [PDF] |
||||
![]() |
R. M Cubbon, A. Rajwani, and S. B Wheatcroft The impact of insulin resistance on endothelial function, progenitor cells and repair Diabetes and Vascular Disease Research, June 1, 2007; 4(2): 103 - 111. [Abstract] [PDF] |
||||
![]() |
P. Leeson Pediatric Prevention of Atherosclerosis: Targeting Early Variation in Vascular Biology Pediatrics, June 1, 2007; 119(6): 1204 - 1206. [Full Text] [PDF] |
||||
![]() |
U. Landmesser, S. Spiekermann, C. Preuss, S. Sorrentino, D. Fischer, C. Manes, M. Mueller, and H. Drexler Angiotensin II Induces Endothelial Xanthine Oxidase Activation: Role for Endothelial Dysfunction in Patients With Coronary Disease Arterioscler. Thromb. Vasc. Biol., April 1, 2007; 27(4): 943 - 948. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Melikian, S. B. Wheatcroft, O. S. Ogah, C. Murphy, P. J. Chowienczyk, A. S. Wierzbicki, T. A.B. Sanders, B. Jiang, E. R. Duncan, A. M. Shah, et al. Asymmetric Dimethylarginine and Reduced Nitric Oxide Bioavailability in Young Black African Men Hypertension, April 1, 2007; 49(4): 873 - 877. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Barac, U. Campia, and J. A. Panza Methods for Evaluating Endothelial Function in Humans Hypertension, April 1, 2007; 49(4): 748 - 760. [Full Text] [PDF] |
||||
![]() |
J. E. Deanfield, J. P. Halcox, and T. J. Rabelink Endothelial Function and Dysfunction: Testing and Clinical Relevance Circulation, March 13, 2007; 115(10): 1285 - 1295. [Full Text] [PDF] |
||||
![]() |
J. M. Lee, C. Shirodaria, C. E Jackson, M. D Robson, C. Antoniades, J. M Francis, F. Wiesmann, K. M Channon, S. Neubauer, and R. P Choudhury Multi-modal magnetic resonance imaging quantifies atherosclerosis and vascular dysfunction in patients with type 2 diabetes mellitus Diabetes and Vascular Disease Research, March 1, 2007; 4(1): 44 - 48. [Abstract] [PDF] |
||||
![]() |
M. S. Tonetti, F. D'Aiuto, L. Nibali, A. Donald, C. Storry, M. Parkar, J. Suvan, A. D. Hingorani, P. Vallance, and J. Deanfield Treatment of Periodontitis and Endothelial Function N. Engl. J. Med., March 1, 2007; 356(9): 911 - 920. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Krotz, M. Keller, S. Derflinger, H. Schmid, T. Gloe, F. Bassermann, J. Duyster, C. D. Cohen, C. Schuhmann, V. Klauss, et al. Mycophenolate Acid Inhibits Endothelial NAD(P)H Oxidase Activity and Superoxide Formation by a Rac1-Dependent Mechanism Hypertension, January 1, 2007; 49(1): 201 - 208. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Morita, T. Tsukamoto, M. Naya, K. Noriyasu, M. Inubushi, T. Shiga, C. Katoh, Y. Kuge, H. Tsutsui, and N. Tamaki Smoking Cessation Normalizes Coronary Endothelial Vasomotor Response Assessed with 15O-Water and PET in Healthy Young Smokers J. Nucl. Med., December 1, 2006; 47(12): 1914 - 1920. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Imanishi, K. Kobayashi, A. Kuroi, S. Mochizuki, M. Goto, K. Yoshida, and T. Akasaka Effects of Angiotensin II on NO Bioavailability Evaluated Using a Catheter-Type NO Sensor Hypertension, December 1, 2006; 48(6): 1058 - 1065. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Waxman, F. Ishibashi, and J. E. Muller Detection and Treatment of Vulnerable Plaques and Vulnerable Patients: Novel Approaches to Prevention of Coronary Events Circulation, November 28, 2006; 114(22): 2390 - 2411. [Full Text] [PDF] |
||||
![]() |
G. P. Rossi, G. Maiolino, M. Zanchetta, D. Sticchi, L. Pedon, M. Cesari, D. Montemurro, R. De Toni, S. Zavattiero, and A. C. Pessina The T-786C Endothelial Nitric Oxide Synthase Genotype Predicts Cardiovascular Mortality in High-Risk Patients J. Am. Coll. Cardiol., September 19, 2006; 48(6): 1166 - 1174. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Schwartz Invited Commentary: Ripeness Is All Am. J. Epidemiol., September 1, 2006; 164(5): 434 - 436. [Full Text] [PDF] |
||||
![]() |
S. E. Petersen, F. Wiesmann, L. E. Hudsmith, M. D. Robson, J. M. Francis, J. B. Selvanayagam, S. Neubauer, and K. M. Channon Functional and Structural Vascular Remodeling in Elite Rowers Assessed by Cardiovascular Magnetic Resonance J. Am. Coll. Cardiol., August 15, 2006; 48(4): 790 - 797. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J Roman, T. Z Naqvi, J. M Gardin, M. Gerhard-Herman, M. Jaff, and E. Mohler American Society of Echocardiography Report: Clinical application of noninvasive vascular ultrasound in cardiovascular risk stratification: a report from the American Society of Echocardiography and the Society for Vascular Medicine and Biology Vascular Medicine, August 1, 2006; 11(3): 201 - 211. [PDF] |
||||
![]() |
I. J. Goldberg and H. M. Dansky Diabetic Vascular Disease: An Experimental Objective Arterioscler. Thromb. Vasc. Biol., August 1, 2006; 26(8): 1693 - 1701. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Bugiardini, O. Manfrini, and G. M. De Ferrari Unanswered questions for management of acute coronary syndrome: risk stratification of patients with minimal disease or normal findings on coronary angiography. Arch Intern Med, July 10, 2006; 166(13): 1391 - 1395. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Brown, Y. Chu, D. D. Lund, D. D. Heistad, and F. M. Faraci Gene transfer of extracellular superoxide dismutase protects against vascular dysfunction with aging Am J Physiol Heart Circ Physiol, June 1, 2006; 290(6): H2600 - H2605. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Vasan Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations Circulation, May 16, 2006; 113(19): 2335 - 2362. [Full Text] [PDF] |
||||
![]() |
C. R. Lee, K. E. North, M. S. Bray, M. Fornage, J. M. Seubert, J. W. Newman, B. D. Hammock, D. J. Couper, G. Heiss, and D. C. Zeldin Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study Hum. Mol. Genet., May 15, 2006; 15(10): 1640 - 1649. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Yang and X.-F. Ming Recent advances in understanding endothelial dysfunction in atherosclerosis. Clin. Med. Res., March 1, 2006; 4(1): 53 - 65. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Campia, L. A. Matuskey, and J. A. Panza Peroxisome Proliferator-Activated Receptor-{gamma} Activation With Pioglitazone Improves Endothelium-Dependent Dilation in Nondiabetic Patients With Major Cardiovascular Risk Factors Circulation, February 14, 2006; 113(6): 867 - 875. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. N. Bairey Merz, L. J. Shaw, S. E. Reis, V. Bittner, S. F. Kelsey, M. Olson, B. D. Johnson, C. J. Pepine, S. Mankad, B. L. Sharaf, et al. Insights From the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part II: Gender Differences in Presentation, Diagnosis, and Outcome With Regard to Gender-Based Pathophysiology of Atherosclerosis and Macrovascular and Microvascular Coronary Disease J. Am. Coll. Cardiol., February 7, 2006; 47(3_Suppl_S): S21 - S29. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Quyyumi Women and Ischemic Heart Disease: Pathophysiologic Implications From the Women's Ischemia Syndrome Evaluation (WISE) Study and Future Research Steps J. Am. Coll. Cardiol., February 7, 2006; 47(3_Suppl_S): S66 - S71. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. H. Yang, J. P. McConnell, R. J. Lennon, G. W. Barsness, G. Pumper, S. J. Hartman, C. S. Rihal, L. O. Lerman, and A. Lerman Lipoprotein-Associated Phospholipase A2 Is an Independent Marker for Coronary Endothelial Dysfunction in Humans Arterioscler. Thromb. Vasc. Biol., January 1, 2006; 26(1): 106 - 111. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. L. Mills, H. Tornqvist, S. D. Robinson, M. Gonzalez, K. Darnley, W. MacNee, N. A. Boon, K. Donaldson, A. Blomberg, T. Sandstrom, et al. Diesel Exhaust Inhalation Causes Vascular Dysfunction and Impaired Endogenous Fibrinolysis Circulation, December 20, 2005; 112(25): 3930 - 3936. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Willoughby, S. Stewart, A. S. Holmes, Y. Y. Chirkov, and J. D. Horowitz Platelet Nitric Oxide Responsiveness: A Novel Prognostic Marker in Acute Coronary Syndromes Arterioscler. Thromb. Vasc. Biol., December 1, 2005; 25(12): 2661 - 2666. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Campen, N. S. Babu, G. A. Helms, S. Pett, J. Wernly, R. Mehran, and J. D. McDonald Nonparticulate Components of Diesel Exhaust Promote Constriction in Coronary Arteries from ApoE-/- Mice Toxicol. Sci., November 1, 2005; 88(1): 95 - 102. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Zhang, A. Zhang, D.E. Kohan, R.D. Nelson, F.J. Gonzales, T. Yang, C. Schmidt-Lucke, L. Rossig, S. Fichtlscherer, M. Vasa, et al. Edema and Congestive Heart Failure from Thiazolidone Insulin Sensitizers--Excess Sodium Reabsoption in the Collecting Duct: Collecting Duct-Specific Deletion of Peroxisome Proliferator-Activated Receptor {gamma} Blocks Thiazolidinedione-Induced Fluid Retention. Proc Nat Acad Sci U S A 102: 9406-9411, 2005 J. Am. Soc. Nephrol., November 1, 2005; 16(11): 3139 - 3142. [Full Text] [PDF] |
||||
![]() |
K. E Pyke and M. E Tschakovsky The relationship between shear stress and flow-mediated dilatation: implications for the assessment of endothelial function J. Physiol., October 15, 2005; 568(2): 357 - 369. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Wildhirt, C. Schulze, N. Conrad, R. Bauernschmitt, R. Lange, and W. von Scheidt Persistently increased systemic, but not cardiac-specific, adhesion molecule expression and coronary endothelial dysfunction in human cardiac allografts J. Thorac. Cardiovasc. Surg., October 1, 2005; 130(4): 1175 - 1175. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Schwaiger, S. Ziegler, and S. G. Nekolla PET/CT: Challenge for Nuclear Cardiology J. Nucl. Med., October 1, 2005; 46(10): 1664 - 1678. [Abstract] [Full Text] [PDF] |
||||
![]() |
J P J Halcox and J E Deanfield Childhood origins of endothelial dysfunction Heart, October 1, 2005; 91(10): 1272 - 1274. [Full Text] [PDF] |
||||
![]() |
J A Vita Endothelial function and clinical outcome Heart, October 1, 2005; 91(10): 1278 - 1279. [Full Text] [PDF] |
||||
![]() |
N. P. Johnson and K. L. Gould Clinical Evaluation of a New Concept: Resting Myocardial Perfusion Heterogeneity Quantified by Markovian Analysis of PET Identifies Coronary Microvascular Dysfunction and Early Atherosclerosis in 1,034 Subjects J. Nucl. Med., September 1, 2005; 46(9): 1427 - 1437. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Oechslin, W. Kiowski, R. Schindler, A. Bernheim, B. Julius, and H. P. Brunner-La Rocca Systemic Endothelial Dysfunction in Adults With Cyanotic Congenital Heart Disease Circulation, August 23, 2005; 112(8): 1106 - 1112. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Neishi, S. Mochizuki, T. Miyasaka, T. Kawamoto, T. Kume, R. Sukmawan, M. Tsukiji, Y. Ogasawara, F. Kajiya, T. Akasaka, et al. Evaluation of bioavailability of nitric oxide in coronary circulation by direct measurement of plasma nitric oxide concentration PNAS, August 9, 2005; 102(32): 11456 - 11461. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.-H. Huang, L.-C. Chen, H.-B. Leu, P. Y.-A. Ding, J.-W. Chen, T.-C. Wu, and S.-J. Lin Enhanced Coronary Calcification Determined by Electron Beam CT Is Strongly Related to Endothelial Dysfunction in Patients With Suspected Coronary Artery Disease Chest, August 1, 2005; 128(2): 810 - 815. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Thanyasiri, D. S. Celermajer, and M. R. Adams Endothelial dysfunction occurs in peripheral circulation patients with acute and stable coronary artery disease Am J Physiol Heart Circ Physiol, August 1, 2005; 289(2): H513 - H517. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Wu, L. Liu, M. Meydani, and S. N. Meydani Vitamin E Increases Production of Vasodilator Prostanoids in Human Aortic Endothelial Cells through Opposing Effects on Cyclooxygenase-2 and Phospholipase A2 J. Nutr., August 1, 2005; 135(8): 1847 - 1853. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.A. Lteif, K. Han, and K.J. Mather Obesity, Insulin Resistance, and the Metabolic Syndrome: Determinants of Endothelial Dysfunction in Whites and Blacks Circulation, July 5, 2005; 112(1): 32 - 38. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. A. Arenas, S. J. Armstrong, Y. Xu, and S. T. Davidge Chronic Tumor Necrosis Factor-{alpha} Inhibition Enhances NO Modulation of Vascular Function in Estrogen-Deficient Rats Hypertension, July 1, 2005; 46(1): 76 - 81. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. Witte, J. Westerink, E. J. de Koning, Y. van der Graaf, D. E. Grobbee, and M. L. Bots Is the Association Between Flow-Mediated Dilation and Cardiovascular Risk Limited to Low-Risk Populations? J. Am. Coll. Cardiol., June 21, 2005; 45(12): 1987 - 1993. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Abrams Chronic Stable Angina N. Engl. J. Med., June 16, 2005; 352(24): 2524 - 2533. [Full Text] [PDF] |
||||
![]() |
H. Gupta, C. R. White, S. Handattu, D. W. Garber, G. Datta, M. Chaddha, L. Dai, S. H. Gianturco, W. A. Bradley, and G.M. Anantharamaiah Apolipoprotein E Mimetic Peptide Dramatically Lowers Plasma Cholesterol and Restores Endothelial Function in Watanabe Heritable Hyperlipidemic Rabbits Circulation, June 14, 2005; 111(23): 3112 - 3118. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. O'Neill, A. Veves, A. Zanobetti, J. A. Sarnat, D. R. Gold, P. A. Economides, E. S. Horton, and J. Schwartz Diabetes Enhances Vulnerability to Particulate Air Pollution-Associated Impairment in Vascular Reactivity and Endothelial Function Circulation, June 7, 2005; 111(22): 2913 - 2920. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Schmidt-Lucke, L. Rossig, S. Fichtlscherer, M. Vasa, M. Britten, U. Kamper, S. Dimmeler, and A. M. Zeiher Reduced Number of Circulating Endothelial Progenitor Cells Predicts Future Cardiovascular Events: Proof of Concept for the Clinical Importance of Endogenous Vascular Repair Circulation, June 7, 2005; 111(22): 2981 - 2987. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Koga, S. Sugiyama, K. Kugiyama, K. Watanabe, H. Fukushima, T. Tanaka, T. Sakamoto, M. Yoshimura, H. Jinnouchi, and H. Ogawa Elevated Levels of VE-Cadherin-Positive Endothelial Microparticles in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease J. Am. Coll. Cardiol., May 17, 2005; 45(10): 1622 - 1630. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. H. Schindler, E. U. Nitzsche, H. R. Schelbert, M. Olschewski, J. Sayre, M. Mix, I. Brink, X.-L. Zhang, M. Kreissl, N. Magosaki, et al. Positron Emission Tomography-Measured Abnormal Responses of Myocardial Blood Flow to Sympathetic Stimulation Are Associated With the Risk of Developing Cardiovascular Events J. Am. Coll. Cardiol., May 3, 2005; 45(9): 1505 - 1512. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Sciacqua, A. Scozzafava, A. Pujia, R. Maio, F. Borrello, F. Andreozzi, M. Vatrano, S. Cassano, M. Perticone, G. Sesti, et al. Interaction between vascular dysfunction and cardiac mass increases the risk of cardiovascular outcomes in essential hypertension Eur. Heart J., May 1, 2005; 26(9): 921 - 927. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. B. Vallbracht, P. L. Schwimmbeck, U. Kuhl, U. Rauch, B. Seeberg, and H.-P. Schultheiss Differential Aspects of Endothelial Function of the Coronary Microcirculation Considering Myocardial Virus Persistence, Endothelial Activation, and Myocardial Leukocyte Infiltrates Circulation, April 12, 2005; 111(14): 1784 - 1791. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Passauer, F. Pistrosch, E. Bussemaker, G. Lassig, K. Herbrig, and P. Gross Reduced Agonist-Induced Endothelium-Dependent Vasodilation in Uremia Is Attributable to an Impairment of Vascular Nitric Oxide J. Am. Soc. Nephrol., April 1, 2005; 16(4): 959 - 965. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Bugiardini and C. N. Bairey Merz Angina With "Normal" Coronary Arteries: A Changing Philosophy JAMA, January 26, 2005; 293(4): 477 - 484. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Terashima, C. H. Meyer, B. G. Keeffe, E. J. Putz, E. de la Pena-Almaguer, P. C. Yang, B. S. Hu, D. G. Nishimura, and M. V. McConnell Noninvasive assessment of coronary vasodilation using magnetic resonance angiography J. Am. Coll. Cardiol., January 4, 2005; 45(1): 104 - 110. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Patti, V. Pasceri, R. Melfi, C. Goffredo, M. Chello, A. D'Ambrosio, R. Montesanti, and G. Di Sciascio Impaired Flow-Mediated Dilation and Risk of Restenosis in Patients Undergoing Coronary Stent Implantation Circulation, January 4, 2005; 111(1): 70 - 75. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A Vita Polyphenols and cardiovascular disease: effects on endothelial and platelet function Am. J. Clinical Nutrition, January 1, 2005; 81(1): 292S - 297S. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Ghani, A. Shuaib, A. Salam, A. Nasir, U. Shuaib, T. Jeerakathil, F. Sher, F. O'Rourke, A. M. Nasser, B. Schwindt, et al. Endothelial Progenitor Cells During Cerebrovascular Disease Stroke, January 1, 2005; 36(1): 151 - 153. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2002 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |